A Study of CD4, CCR3, CCR4, CCR5, CXCR3 Expression in Peripheral Blood Lymphocytes of Patients with Gastric Cancer

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Epidemiology and Biostatistics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Based on the different expression of chemokine receptors in immune cells, we hypothesized that there would be an alteration in the relative expression of these receptors by T helper cells (Th1 and Th2) during the progression of a malignancy.Methods: Peripheral blood mononuclear cells (PBMC) from 27 patients and 27 controls were studied. The percentage of CD4+ T cells expressing chemokine receptors (before and after gastrectomy) was determined by flow cytometry using anti-CD4 and one of the following chemokine receptor antibodies: anti-CC chemokine receptor (CCR) type 5 (CCR5), anti-CXC chemokine receptor 3 (CXCR3), anti-CCR3 and anti-CCR4.Findings: The mean percentage of CD4/CCR5 expressing cells was 1.23 ± 0.90%, 0.83 ± 0.34%, and 1.34 ± 0.74% in control, and pre- and post-operation groups, respectively. The expressing cells were different between pre- and post-gastrectomy groups (P = 0.001). The expression of CD4/CXCR3 cells in control, and pre- and post-operation groups were 19.09 ± 8.40%, 16.95 ± 5.71%, and 25.08 ± 9.31%, respectively. The expression of CXCR3 cells increased significantly in patients after operation (P = 0.001). Pearson's correlation analysis showed an independent correlation between CCR5 and CXCR3 expression before and after the operation (r = -0.091; P = 0.513 before operation and r = 0.0267; P = 0.0177 after operation). The expression of CD4/CCR3 cells in control, and pre- and post-operation groups were 0.75 ± 0.93%, 0.57 ± 0.46%, and 0.62 ± 0.42%, respectively with no difference between pre- and post-operation groups (P = 0.707). The corresponding values for CD4/CCR4 cells were 26.80 ± 10.36%, 32.29 ± 9.00%, and 31.69 ± 8.76%. While a significant difference was observed between control and pre-treatment groups (P = 0.042), differences between post-operation and control groups (P = 0.067) and pre- and post-operation groups (P = 0.513) were not significant. Pearson's correlation analysis showed no relationship between CCR3 and CCR4 expression (r = 0.211; P = 0.126). The only significant correlation was detected between CCR3 and CCR5 (r = 0.321; P = 0.018). Conclusion: Due to low expression of CCR5 in Th1 cells and CCR3 in Th2 cells, these receptors are not appropriate for clinical evaluation. On the other hand, CXCR3 and CCR4 seem to be more valuable in clinical assessments of gastric cancer.

Keywords

References

  1. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006; 25(3): 333-56.
  2. Viola A, Contento RL, Molon B. T cells and their partners: The chemokine dating agency. Trends Immunol 2006; 27(9): 421-7.
  3. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19(12): 568-74.
  4. Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg 1999; 177(3): 203-8.
  5. Reinartz S, Boerner H, Koehler S, Von RA, Schlebusch H, Wagner U. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report. Hybridoma 1999; 18(1): 41-5.
  6. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 1999; 162(4): 2399-405.
  7. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82(4): 568-73.
  8. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999; 21(3): 339-59.
  9. De ST, Van MM, De BG, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27(5): 1229-35.
  10. Yang P, Qiu G, Wang S, Su Z, Chen J, Wang S, et al. The mutations of Th1 cell-specific T-box transcription factor may be associated with a predominant Th2 phenotype in gastric cancers. Int J Immunogenet 2010; 37(2): 111-5.
  11. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17(3): 138-46.
  12. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007; 256(2): 137-65.
  13. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-820.
  14. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007; 109(12): 2392-404.
  15. Sugasawa H, Ichikura T, Kinoshita M, Ono S, Majima T, Tsujimoto H, et al. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 2008; 122(11): 2535-41.
  16. Murphy KM, Travers P, Walport M, Janeway C. Janeway's Immunobiology. 8th ed. United States: Garland Science; 2011.
  17. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190(5): 617-27.
  18. Fujii K, Sonoda K, Izumi K, Shiraishi N, Adachi Y, Kitano S. T lymphocyte subsets and Th1/Th2 balance after laparoscopy-assisted distal gastrectomy. Surg Endosc 2003; 17(9): 1440-4.
  19. Liu XL, Gao J, Han CZ, Qiao LJ. Pre- and post-chemotherapy expressions of Th1 and Th2 type cytokines and their clinical significance in gastric cancer patients. Zhonghua Zhong Liu Za Zhi 2008; 30(11): 844-7. [In Chinese]
  20. Macey GM. Flow Cytometry: Principles and Applications. New York, NY: Humana Press; 2007.
  21. Cavallo F, Curcio C, Forni G. Immunotherapy and immunoprevention of cancer: where do we stand? Expert Opin Biol Ther 2005; 5(5): 717-26.
  22. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997; 150(5): 1723-34.
  23. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112(5): 1557-69.
  24. Paul EW. Fundamental Immunology. Philadelphia, PA: Lippincott williams and wilkins; 2008.
  25. Asano N, Suzuki R, Ohshima K, Kagami Y, Ishida F, Yoshino T, et al. Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. Int J Hematol 2010; 91(3): 426-35.
  26. Yoon SH, Yun SO, Park JY, Won HY, Kim EK, Sohn HJ, et al. Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro. Exp Mol Med 2009; 41(3): 161-70.
  27. Ishikawa M, Nishioka M, Hanaki N, Miyauchi T, Kashiwagi Y, Ioki H, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries. World J Surg Oncol 2009; 7: 7.
  28. Pellegrini P, Berghella AM, Del BT, Cicia S, Adorno D, Casciani CU. Disregulation in Th1 and Th2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42(1): 1-8.
  29. Pellegrini P, Contasta I, Berghella AM, Del BT, Casciani CU, Adorno D. The Th1 and Th2 cytokine network in healthy subjects: suggestions for experimental studies to create prognostic and diagnostic indices for biotherapeutic treatments. Cancer Biother Radiopharm 2000; 15(3): 267-78.
  30. Berghella AM, Pellegrini P, Del BT, Marini M, Tomei E, Adorno D, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from Th1 to Th2 and back. Cancer Immunol Immunother 1998; 45(5): 241-9.
Journal of Isfahan Medical School
Volume 29, Issue 160 - Serial Number 160
September and October 2011
Pages 1760-1773

Files

History

  • Receive Date: 30 January 2012
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics